623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Follicular Lymphoma: Advances in Treatment Approaches


Stefano Luminari, Maria Elena Nizzoli, Annalisa Chiarenza, et al.

Regardless of the regimen prescribed, the FOLL12 study demonstrated the superiority of the standard RM over the response-adapted management after induction in patients with high tumor burden follicular lymphoma treated with RB. This study thus provides the first prospective, non-randomized evidence of RM effectiveness. Both regimens, R-CHOP and RB, had similar efficacy profiles.



Frederick Lansigan, David Jacob Andorsky, Morton Coleman, et al.

This complete analysis of all patients in the induction phase of MAGNIFY further suggests that R2 with its tolerable safety profile is active in patients with R / R FL grade 1-3a and MZL. This includes also rituximab-refractory, double-refractory, and early relapse patients.



Ryan C. Lynch, Abraham Avigdor, Matthew S McKinney, et al.

Parsaclisib monotherapy showed a rapid, sustained response in patients with R/R FL. Parsaclisib had an acceptable safety profile and was generally well tolerated. With these data, the authors suggest that parsaclisib may be a favorable treatment option for patients with R/R FL.



Craig A. Portell, Opeyemi Jegede, Nina D. Wagner-Johnston, et al.

The Study reached its primary endpoint, but the combination of OB-VEN with 800 mg for 10 days plus mO unfortunately does not show an acceptable benefit-risk profile.



Brad S. Kahl, Fangxin Hong, Christopher Peterson, et al.

In treatment-naïve follicular lymphoma with a low tumor burden, MR was superior to RR in terms of delay to first cytotoxic therapy and response time. There has been a trend towards reducing the risk of histological transformation. MR did not improve overall survival. Rituximab was highly effective in delaying the time to first cytotoxic therapy in both dosing strategies.



Brendan Beaton, Sarah C Sasson, Katherine Rankin, et al.

Treatment-naive patients (TNP) had a better response than treated patients in the FL cohort, but not significantly different from healthy controls. WM-patients with BTKi had a significantly reduced response compared to TNP. The same reduction was not observed in patients with chemotherapy-rituximab. FL patients with chemotherapy-rituximab had a significantly reduced response compared to TNP. The full dates will be presented in the oral session.